IP
ONCY

Intellectus Partners’s Oncolytics Biotech ONCY Stock Holding History

Intellectus Partners’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,105
Closed -$8K – 431
2018
Q3 		$8K Buy
+2,105
New +$9.78K ﹤0.01% 493

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Intellectus Partners's ONCY Position: Q4 2018 in Review

Intellectus Partners sold out of Oncolytics Biotech (ONCY) in Q4 2018, closing a stake of 2,105 shares — an estimated $8K sold.

Intellectus Partners first reported a position in ONCY in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 21 funds tracked by Wall St. Rank hold ONCY as of Q4 2018.

  • Intellectus Partners reported no remaining Oncolytics Biotech position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 2,105 Oncolytics Biotech shares in Q4 2018, an estimated $8K.
  • Intellectus Partners first reported a position in Oncolytics Biotech in Q3 2018 and held it in 1 quarter.
  • Intellectus Partners's Oncolytics Biotech position peaked at $8K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.